KLK3 and prostate cancer: For most of the men included, early access to prostate-specific antigen (PSA) testing was limited.<h4>Results</h4>In full cohort analyses, a PRS at or above the median (vs. below the median) shows a strong association with prostate cancer incidence (hazard ratio (HR) 3.02, 95% CI 2.78-3.28) and, somewhat stronger, with prostate cancer mortality (HR 3.26, 95% CI 2.63-4.04).